ID

21921

Beskrivning

The present pharmacokinetic study is designed to assess the pharmacokinetics of RSG XR as monotherapy in patients with mild Alzheimer's disease (AD) as such information will not be obtained from the current phase III trials . The study aims to enroll fourteen patients (seven of each APOE genotype). Each patient will receive a single oral dose of 4mg of RSG XR in the morning under fasted conditions and PK samples will be taken up to 36h. GSK Source & Descriptions: https://clinicaltrials.gov/ct2/show/NCT00688207?term=NCT00688207&rank=1

Länk

https://clinicaltrials.gov/ct2/show/NCT00688207?term=NCT00688207&rank=1

Nyckelord

Versioner (2)
  1. 2017-05-08 2017-05-08 -
  2. 2017-05-20 2017-05-20 -
Uppladdad den

8 maj 2017

DOI

För en begäran logga in.

Licens

Creative Commons BY-NC 3.0
Modellkommentarer :

Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.

Tillbaka till modellkommentarer
Itemgroup-kommentar för :

Item-kommentar för :

Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.

Study Conclusion Mild Alzheimer's Disease to Assess the of Extended Release Formulation of Rosiglitazone NCT00688207 / GSK-AVA109941

Engelsk

Study Conclusion Mild Alzheimer's Disease to Assess the of Extended Release Formulation of Rosiglitazone NCT00688207 / GSK-AVA109941

1 Formulär  
Study Conclusion
Beskrivning

Study Conclusion

Alias
UMLS CUI-1
C1707478
UMLS CUI-2
C0008976
Date of subject completion or withdrawal
Beskrivning

Date of completion

Datatyp

date

Alias
UMLS CUI [1]
C0011008
Was the subject withdrawn from the study?
Beskrivning

Withdrawal

Datatyp

boolean

Alias
UMLS CUI [1]
C2349954
If yes, check one primary reason for withdrawal:
Beskrivning

Reason for withdrawal

Datatyp

integer

Alias
UMLS CUI [1,1]
C2349954
UMLS CUI [1,2]
C0392360
Specify "Investigator discretion":
Beskrivning

Specification

Datatyp

text

Alias
UMLS CUI [1]
C2348235
Tillbaka till toppen

Similar models

Study Conclusion Mild Alzheimer's Disease to Assess the of Extended Release Formulation of Rosiglitazone NCT00688207 / GSK-AVA109941

1 Formulär
Name
Typ
Description | Question | Decode (Coded Value)
Datatyp
Alias
Item Group
Study Conclusion
C1707478 (UMLS CUI-1)
C0008976 (UMLS CUI-2)
Date of completion
Item
Date of subject completion or withdrawal
date
C0011008 (UMLS CUI [1])
Withdrawal
Item
Was the subject withdrawn from the study?
boolean
C2349954 (UMLS CUI [1])
Item
If yes, check one primary reason for withdrawal:
integer
C2349954 (UMLS CUI [1,1])
C0392360 (UMLS CUI [1,2])
Reason for withdrawal
Code List
If yes, check one primary reason for withdrawal:
CL Item
Adverse event -> Record details on the Non-Serious Adverse Events or Serious Adverse Event pages as appropriate  (1)
CL Item
Protocol deviation (2)
CL Item
Subject reached protocol defined stopping criteria (3)
CL Item
Study closed/terminated (4)
CL Item
Lost to follow-up (5)
CL Item
Investigator discretion (Only check if none of the other primary reasons are appropriate) (6)
CL Item
Withdrew consent (Only check if none of the other primary reasons are appropriate) (7)
Specification
Item
Specify "Investigator discretion":
text
C2348235 (UMLS CUI [1])
Tillbaka till toppen 

Kontakt

Använd detta formulär för feedback, frågor och förslag på förbättringar.

Fält markerade med * är obligatoriska.

Hjälp

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial